San Francisco, USA and Suzhou, ChinaMay 13, 2026 /PRNewswire/ — Innovent Biologics, Inc. (HKEX: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases such as oncology, autoimmune diseases, metabolic and cardiovascular diseases, and ophthalmology, announced today that it will present clinical and preclinical research data, including those for Mazdutide and its next-generation weight loss and metabolic pipeline, at the 2026 American Diabetes Association (ADA) Scientific Sessions. The conference will be held from June 5 to 8, 2026, in New Orleans, USA.
Dr. Lei Qian, Chief R&D Officer of the Integrated Pipeline at Innovent Biologics, stated: “At this year’s ADA Annual Meeting, Innovent will showcase a series of our latest research findings in the weight loss and metabolic field, which is of great significance to our goal of becoming an emerging leading brand and innovation driver in metabolic therapy. The multiple oral presentations on Mazdutide, covering clinical data from patients with type 2 diabetes and obesity, adults with obesity, and adolescents with obesity, systematically demonstrate its differentiated advantages as a GCG/GLP-1 dual receptor agonist in weight loss, blood glucose control, and metabolic improvement across diverse populations. Facing the still significant unmet needs in the global obesity treatment landscape, we have established a comprehensive global innovative pipeline. The clinical or preclinical data presented at this conference for IBI3032 (oral daily small molecule GLP-1 receptor agonist), IBI3042 (oral weekly small molecule GLP-1 receptor agonist), and early-stage projects such as IBI3040 (Amylin) and IBI3046 (INHBE siRNA) represent important milestones for this pipeline. We aim to provide more scientific, comprehensive, and long-term treatment options for patients with obesity and metabolic diseases worldwide through better tolerability, reduced muscle loss, more convenient and longer-interval dosing regimens, more sustained weight loss effects, and comprehensive intervention for related comorbidities.”
Summary of research results is as follows:
Oral Presentations Related to Mazdutide
- Title: Mazdutide vs. Semaglutide in Chinese Adults with Type 2 Diabetes and Obesity (DREAMS-3): A Randomized, Open-Label Phase 3b Clinical Trial
Abstract Number: 1226-OR
Time: June 7, 2026 (Sunday) 8:15 AM – 8:30 AM (Central Time)
Presenter: Professor Linong Ji, Peking University People’s Hospital - Title: Efficacy and Safety of Mazdutide 9 mg in Chinese Adults with Obesity: Results from the Phase 3 GLORY-2 Clinical Trial
Abstract Number: 1225-OR
Time: June 7, 2026 (Sunday) 8:00 AM – 8:15 AM (Central Time)
Presenter: Dr. Leili Gao, Peking University People’s Hospital - Title: Safety, Tolerability, and Pharmacokinetics of Mazdutide in Chinese Adolescents with Obesity: A Phase 1b Clinical Trial
Abstract Number: 1133-OR
Presentation Time: June 5, 2026 (Friday) 5:30 PM – 5:45 PM (Central Time)
Presenter: Professor Chunxiu Gong, Beijing Children’s Hospital, Capital Medical University
The three studies above cover diverse populations including adults with type 2 diabetes and obesity, adults with obesity, and adolescents with obesity. They will systematically demonstrate the clinical value of Mazdutide in weight management, blood glucose control, and metabolic improvement, further solidifying its differentiated advantages as a next-generation GCG/GLP-1 dual receptor agonist in glucose lowering and fat reduction.
Poster Presentations Related to Mazdutide
4. Title: Mazdutide Attenuates MASH and Liver Fibrosis through Hepatocyte-Hepatic Stellate Cell Crosstalk*
Abstract Number: 2505-P
Time: June 7, 2026 (Sunday) 12:30 PM – 1:30 PM (Central Time)
Presenter: Dr. Lingfeng Zhang, China Pharmaceutical University
5. Title: GLP-1R/GCGR Agonist Improves MAFLD through Reprogramming Systemic and Hepatic Metabolism*
Abstract Number: 1686-P
Time: June 7, 2026 (Sunday) 12:30 PM – 1:30 PM (Central Time)
Presenter: Dr. Danni Gao, Beijing Hospital
*The above two studies are investigator-initiated trials (IITs)
Poster Presentations Related to Next-Generation Innovative Pipeline
- Title: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI3032, a Novel Oral Non-Peptide GLP-1 Receptor Agonist: Single and Multiple Ascending Dose Studies in Chinese Adults
Abstract Number: 1690-P
Time: June 7, 2026 (Sunday) 12:30 PM – 1:30 PM (Central Time)
Presenter: Dr. Huan Deng, Innovent Biologics - Title: IBI3032: An Orally Bioavailable Non-Peptide GLP-1 Receptor Agonist Advancing to Phase 1 Clinical Trials
Abstract Number: 1678-P
Time: June 7, 2026 (Sunday) 12:30 PM – 1:30 PM (Central Time)
Presenter: Dr. Decheng Ren, Innovent Biologics - Title: IBI3040: A Novel Amylin Analog Demonstrating Superior Weight Loss in Preclinical Models
Abstract Number: 3077-LB
Time: June 7, 2026 (Sunday) 12:30 PM – 1:30 PM (Central Time)
Presenter: Dr. Yuqiang Niu, Innovent Biologics - Title: IBI3042: A Novel Oral Once-Weekly Small Molecule GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes and Obesity
Abstract Number: 2543-P
Time: June 8, 2026 (Monday) 12:30 PM – 1:30 PM (Central Time)
Presenter: Dr. Decheng Ren, Innovent Biologics - Title: IBI3046: An siRNA Targeting INHBE Achieving High-Quality, Long-Lasting Weight Control in Preclinical Studies
Abstract Number: 2662-P
Time: June 8, 2026 (Monday) 12:30 PM – 1:30 PM (Central Time)
Presenter: Dr. Xiguang Zhang, Innovent Biologics
The next-generation oral GLP-1 receptor agonists represented by IBI3032 and IBI3042, along with multiple R&D pipelines such as IBI3040 (Amylin) and IBI3046 (INHBE siRNA), constitute Innovent’s innovative and differentiated global portfolio in weight loss and related metabolic comorbidities. These projects focus on addressing global challenges still present with current GLP-1 therapies, including improving tolerability, reducing muscle loss, extending dosing intervals, maintaining long-term weight loss efficacy, and comprehensively managing comorbidities such as cardiovascular disease and fatty liver disease.
About Innovent Biologics
“Start with Integrity, Succeed through Action” – Innovent’s mission and goal is to develop high-quality biologics that are affordable to the general public. Founded in 2011, Innovent is dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases such as oncology, autoimmune diseases, metabolic diseases, and ophthalmology, benefiting more lives through our work. The company has 18 approved products: Sintilimab Injection (Tyvyt®), Bevacizumab Injection (Byvasda®), Adalimumab Injection (Sulinno®), Rituximab Injection (Dabohua®), Pemigatinib Tablets (Pemazyre®), Olverembatinib Tablets (Nerlynx®), Ramucirumab Injection (Cyramza®), Selpercatinib Capsules (Retevmo®), Equecabtagene Autoleucel Injection (Fucaso®), Tafolecimab Injection (Sibeprenlimab®), Fuzereisai Tablets (Dabote®), Pirtobrutinib Tablets (Jaypirca®), Taletrectinib Adipate Capsules (Dabole®), Lieritinib Tablets (Aoyixin®), Teprotumumab N01 Injection (Sibemin®), Mazdutide Injection (Xinermei®), Pikankibart Injection (Xinmeiyue®), and Ipilimumab N01 Injection (Daboxin®). Currently, 5 new drug molecules are in Phase 3 or pivotal clinical studies, and an additional 14 new drug candidates have entered clinical research.
The company has entered into over 30 strategic collaborations with international partners such as Eli Lilly, Roche, Takeda, Sanofi, Incyte, and MD Anderson Cancer Center. While continuously innovating and developing its own drugs and pursuing growth, Innovent adheres to a people-centered development philosophy. Over the years, it has always been guided by scientific goodwill, remained patient-centric, cared for patients and their families, and actively fulfilled its social responsibilities. The company has initiated and participated in multiple patient assistance programs, enabling more patients to benefit from advances in life sciences and to afford and access high-quality biologics. To date, Innovent’s patient assistance programs have benefited over 200,000 ordinary patients, with the total value of drug donations reaching RMB 4 billion. Innovent hopes to work together with everyone to improve the development level of China’s biopharmaceutical industry, to meet the public’s need for drug accessibility and the pursuit of a healthy life.
For more information, please visit the company’s website: www.innoventbio.com or the company’s LinkedIn account: www.linkedin.com/
|
Disclaimer: 1. Innovent does not recommend the use of unapproved drugs/indications. |
|
2. Ramucirumab Injection (Cyramza®), Selpercatinib Capsules (Retevmo®), and Pirtobrutinib Tablets (Jaypirca®) were developed by Eli Lilly. |
Forward-Looking Statements
The information released in this press release may contain certain forward-looking statements. These statements are inherently subject to significant risks and uncertainties. When using words such as “anticipate,” “believe,” “predict,” “expect,” “intend,” and other similar expressions, when related to the company, the purpose is to indicate that they are forward-looking statements. The company is under no obligation to continuously update these forward-looking statements.
These forward-looking statements are based on the current views, assumptions, expectations, estimates, projections, and understandings of the company’s management regarding future events at the time the statements are made. These statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond the company’s control and difficult to predict. Therefore, actual results may differ materially from the information contained in the forward-looking statements due to future changes and developments in our business, competitive environment, and political, economic, legal, and social conditions.